GLP-1 receptor agonists and SGLT2 inhibitors protect cardiovascular and renal health through largely indirect mechanisms, with GLP-1 RAs targeting atherosclerosis and SGLT2i targeting heart failure and kidney function.
Complementary organ protectionGLP-1 RAs reduce atherosclerotic events; SGLT2i reduce heart failure and kidney decline — different but additive benefits
What the researchers found
GLP-1 RAs and SGLT2i protect cardiovascular and renal systems through distinct but complementary mechanisms: GLP-1 RAs reduce atherosclerotic events while SGLT2i reduce heart failure and preserve kidney function.
Why it matters
These drugs have transformed diabetes care by offering organ protection beyond blood sugar control. Understanding their mechanisms helps optimize treatment selection and supports their expansion to non-diabetic patients with cardiovascular or kidney disease.
The numbers in context
GLP-1RA: reduced MACE, MI, stroke; SGLT2i: reduced HF, preserved eGFR; low cardiac receptor expression; mortality reduced
How the study worked
Comprehensive mechanistic review of cardiovascular and renal outcome trial data with analysis of molecular mechanisms of GLP-1 RAs and SGLT2 inhibitors.
Who was studied
Review of cardiovascular and renal outcome trials in type 2 diabetes and beyond
What this study cannot tell us
Review limited to mechanisms known at time of publication. Exact mechanisms remain incompletely understood. Head-to-head comparisons between the two classes are limited.
How to read the evidence
Comprehensive mechanistic review synthesizing data from multiple large cardiovascular and renal outcome trials. High-quality evidence base.
When this study was published
Published in 2021, reflecting the expanding indications for both drug classes beyond diabetes.
The bigger picture
The discovery that diabetes drugs can protect the heart and kidneys independent of blood sugar control has been one of the most important developments in medicine in recent years. Understanding the mechanisms is driving their use far beyond diabetes — into heart failure, chronic kidney disease, and potentially other conditions.
Questions still open
- Would combining GLP-1 RAs and SGLT2i provide additive cardiovascular and renal protection?
- What other organ systems might benefit from these drug classes?
- Are the cardiovascular benefits class effects or drug-specific?
Common questions
How do GLP-1 drugs protect the heart differently from SGLT2 inhibitors?
Do you need to have diabetes to benefit from these drugs?
Read the original research
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
Med (New York, N.Y.), 2(11), 1203-1230
Citation
Cherney, David Z I; Udell, Jacob A; Drucker, Daniel J. (2021). Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.. Med (New York, N.Y.), 2(11), 1203-1230. https://doi.org/10.1016/j.medj.2021.10.004